---
title: "Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Cut to $18.55, Implies 13% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286306439.md"
description: "Takeda Pharmaceutical Company Limited's 12-month stock price target has been cut to $18.55, indicating a potential upside of 13%. Analysts' average price target has slightly increased from $19.2 to $19.3, with a range of $15.4 to $21.67. The consensus rating remains a 'Buy' from 12 analysts, comprising 7 Buys and 5 Holds. This information is sourced from FactSet and does not constitute investment advice."
datetime: "2026-05-13T19:20:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286306439.md)
  - [en](https://longbridge.com/en/news/286306439.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286306439.md)
---

# Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Cut to $18.55, Implies 13% Upside

-   According to estimates from 11 analysts, Takeda Pharmaceutical Company Limited stock's average price target has risen from $19.2 to $19.3, with forecasts ranging from $15.4 to $21.67 per share
-   Based on the May 12 closing price, the updated target implies approximately 18% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 7 Buys, 5 Holds and 0 Sells

Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the , and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31](https://longbridge.com/en/news/286837374.md)
- [Takeda Pharmaceutical (NYSE:TAK) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPS](https://longbridge.com/en/news/286621568.md)
- [Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision](https://longbridge.com/en/news/286840681.md)
- [US jury to decide if Takeda delayed generic constipation drug](https://longbridge.com/en/news/286455075.md)
- [Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results](https://longbridge.com/en/news/286858624.md)